Search Results - guangrong+zheng

6 Results

Sort By:

Oncolytic Dual Targeting Agent for Treating Diseases Associated with the Epstein-Barr Virus (EBV)

Identifies and Eliminates Specific Enzymes that Cause Cell Growth in EBV-Associated Cancers This dual targeting agent reactivates the Epstein-Barr virus (EBV) to treat cancer patients by targeting enzymes that support the EBV latent state and thereby, uncontrolled EBV-cancer cell growth. The Epstein-Barr virus is a human herpesvirus infecting most...

Published: 1/20/2026 | Inventor(s): Sumita Bhaduri-McIntosh, Yufeng Xiao, Guangrong Zheng, Michael McIntosh, Beth Rousseau

Keywords(s):

Category(s): Technology Classifications > Human Health Care, Technology Classifications > Human Health Care > Therapeutics

Piperlongumine-Based PROTAC As Potent Anticancer Agent With Reduced Toxicity

Uses Piperlongumine as an E3 Ligase Ligand to Facilitate the Degradation of Cancer-Associated Proteins of Interest This naturally occurring compound with anti-cancer properties has the potential to revolutionize cancer treatment by providing tailored therapies with reduced side effects. Cancer remains a significant health issue in the United States,...

Published: 1/20/2026 | Inventor(s): Guangrong Zheng, Daohong Zhou, Dongwen Lyu, Yaxia Yuan, Xingui Liu, Yufeng Xiao, Wanyi Hu, Jing Pei

Keywords(s):

Category(s): Technology Classifications > Human Health Care > Therapeutics

Method of Treating Obesity-Induced Glucose Intolerance and Liver Fibrosis (UCLA Case No. 2021-323)

UCLA researchers in the School of Engineering have discovered a novel method to treat obesity-induced glucose intolerance and liver fibrosis. BACKGROUND: The CDC reports that 41.9% of adults ages 20 and over are obese. An increased incidence of obesity also increases the rates of comorbidities such at type 2 diabetes mellitus (T2DM), non-alcoholic...

Published: 7/17/2025 | Inventor(s): Zhen Gu

Keywords(s): glucose intolerance, liver fibrosis, Nanoparticles, Notch signaling pathway, obesity

Category(s): Therapeutics > Metabolism And Endocrinology

Anticancer Compounds That Selectively Target and Destroy Cancer-Related Proteins

Demonstrates In Vivo Safety and Efficacy in Breast Cancer Models This set of anticancer compounds selectively degrades or inhibits cancer-related histone deacetylase proteins. These proteins are commonly overexpressed in various cancer types, and class I histone deacetylase proteins activate oncogenes that cause tumor formation, cancer progression,...

Published: 1/20/2026 | Inventor(s): Daiqing Liao, Xuan Zhang, Yufeng Xiao, William Roush, Ryan Stowe, Guangrong Zheng

Keywords(s):

Category(s): Technology Classifications > Human Health Care > Therapeutics

A Method to Prepare Dead Tumor Cells and Use Thereof (UCLA Case No. 2020-179)

SUMMARYUCLA researchers in the Department of Bioengineering have developed a novel method to generate dead tumors cells for use in cancer therapeutics.BACKGROUNDCancer is a deadly disease that causes approximately 10 million yearly deaths across the globe. While solid tumors may often be fully resected by surgery, the treatment of hematologic malignancies...

Published: 7/17/2025 | Inventor(s): Zhen Gu

Keywords(s): Medical Devices and Materials, Oncology, Therapeutics & Vaccines

Category(s): Therapeutics > Oncology

Injectable Biodegradable Polymeric Complex for Glucose-Responsive Insulin Delivery (UCLA Case No. 2021-116)

Summary: UCLA researchers in the department of Bioengineering have developed a biodegradable material that is capable of releasing insulin in the presence of excess glucose mimicking the insulin secretion properties of pancreatic B-cells as a treatment for Diabetes Mellitus.Background: Diabetes mellitus currently affects more than 463 million people...

Published: 2/14/2025 | Inventor(s): Zhen Gu

Keywords(s):

Category(s): Platforms > Drug Delivery > Other Polymers, Therapeutics > Inflammation And Inflammatory Diseases, Therapeutics > Metabolism And Endocrinology